Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Oyster Point Pharma Inc (OYST) USD0.001

Sell:$20.64 Buy:$21.11 Change: $0.16 (0.77%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$20.64
Buy:$21.11
Change: $0.16 (0.77%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$20.64
Buy:$21.11
Change: $0.16 (0.77%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Oyster Point Pharma, Inc. is a clinical stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of pharmaceutical therapies to treat ocular surface diseases. Its lead product candidate is OC-01 (varenicline), a selective nicotinic acetylcholine receptor (nAChR) agonist, which is being developed as a nasal spray to treat the signs and symptoms of dry eye disease (DED). OC-01’s is a mechanism of action, which is designed to re-establish tear film homeostasis by stimulating the trigeminal nerve, activating the TPP and stimulating the glands and cells responsible for natural tear film production. It is sprayed into the anterior portion of the nasal cavity, and stimulates nAChRs located on the chemosensory endings of the trigeminal nerve resulting in cholinergic neurotransmission.

Contact details

Address:
202 Carnegie Ctr Ste 109
PRINCETON
08540-6239
United States
Telephone:
+1 (609) 3829032
Website:
https://oysterpointrx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
OYST
ISIN:
US69242L1061
Market cap:
$529.59 million
Shares in issue:
25.91 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Ali Behbahani
    Chairman of the Board
  • Jeffrey Nau
    President, Chief Executive Officer, Director
  • Daniel Lochner
    Chief Financial Officer
  • Eric Carlson
    Chief Scientific Officer
  • Marian Macsai
    Chief Medical Officer
  • John Snisarenko
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.